Effect of Ulipristal Acetate for Uterine Fibroids

被引:0
|
作者
Deshpande, Preeti Suhas [1 ,2 ]
Deshpande, Suhas Suresh [1 ,2 ]
机构
[1] Ekopa Hosp, Dept Obstet & Gynaecol, Karad, Maharashtra, India
[2] Karad Fertil Res Ctr, Karad, Maharashtra, India
来源
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS | 2019年 / 8卷 / 49期
关键词
Fibroid; Ulipristal Acetate; Menorrhagia; Selective Progesterone Receptor Modulator; SPRM; MANAGEMENT; PLACEBO; SAFETY;
D O I
10.14260/jemds/2019/795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Fibroids are the most common tumours of the female reproductive tract and have been reported to affect 20-40% of women during their reproductive years. Most fibroids are asymptomatic and require no treatment. We wanted to investigate the effectiveness of Ulipristal Acetate in reducing the fibroid volume, and giving symptomatic relief after 3 months treatment. METHODS This is a prospective interventional study conducted among 38 premenopausal women with symptomatic fibroids. They were evaluated clinically for the symptoms reported. Each underwent ultrasound before starting the treatment and after three months of Ulipristal treatment. Some patients had more than one fibroid and so in total the sizes of 56 fibroids were recorded. RESULTS After 3 months of ulipristal acetate treatment, patients had a significant improvement of all symptoms with fibroid volume reduction. CONCLUSIONS Fibroid treatment with ulipristal acetate resulted in a significant improvement of fibroid related symptoms and significant reduction in fibroid volume.
引用
收藏
页码:3675 / 3678
页数:4
相关论文
共 50 条
  • [11] Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids
    Talaulikar, Vikram Sinai
    Manyonda, Isaac
    WOMENS HEALTH, 2014, 10 (06) : 565 - 570
  • [12] Application of ulipristal acetate in female patients with uterine fibroids
    Grzechocinska, Barbara
    Gadomska, Halina
    Zygula, Aleksandra
    Wielgos, Miroslaw
    NEUROENDOCRINOLOGY LETTERS, 2014, 35 (03) : 175 - 178
  • [13] Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial
    Osuga, Yutaka
    Nakano, Yasuaki
    Yamauchi, Yuji
    Takanashi, Masaya
    FERTILITY AND STERILITY, 2021, 116 (01) : 189 - 197
  • [14] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Talaulikar, Vikram S.
    Manyonda, Isaac T.
    ADVANCES IN THERAPY, 2012, 29 (08) : 655 - 663
  • [15] Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues
    Perez-Lopez, F. R.
    CLIMACTERIC, 2015, 18 (02) : 177 - 181
  • [16] Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program
    Donnez, Jacques
    Arriagada, Pablo
    Marciniak, Marcin
    Larrey, Dominique
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1225 - 1232
  • [17] Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
    Bourdet, Alice Trefoux
    Luton, Dominique
    Koskas, Martin
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 321 - 330
  • [18] Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital
    Woodhead, Natalie
    Pounds, Rachel
    Irani, Shirin
    Pradhan, Poonam
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 38 (06) : 813 - 817
  • [19] Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
    Middelkoop, Mei-An
    de Lange, Maria E.
    Clark, T. Justin
    Mol, Ben Willem J.
    Bet, Pierre M.
    Huirne, Judith A. F.
    Hehenkamp, Wouter J. K.
    HUMAN REPRODUCTION, 2022, 37 (05) : 884 - 894
  • [20] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Oliver Pohl
    R. Howard Zobrist
    Jean-Pierre Gotteland
    Reproductive Sciences, 2015, 22 : 476 - 483